Syntimmune Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Syntimmune Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10968
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Syntimmune Inc (Syntimmune) is a clinical-stage biotechnology company that focuses to develop Fc receptor (FcRn) based antibody therapeutics for the treatment of autoimmune diseases. Its lead pipeline products includes SYNT001, an investigational humanized IgG4 monoclonal antibody that inhibits the interaction of FcRn with IgG and IgG immune complexes by binding FcRn at both neutral and acidic pH levels; and SYNT002 that targets FcRn-albumin interactions to support the release of albumin-bound toxins, and protect organs such as the liver from toxicity. The company is developing its products for the treatment of autoimmune diseases in neurology, dermatology and hematology among others. Syntimmune is headquartered in Boston, Massachusetts, the US.

Syntimmune Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syntimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Syntimmune Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Syntimmune Raises USD50 Million in Series B Financing 10
Syntimmune Raises USD8 Million in Final Tranche of Series A Financing Round 11
Syntimmune Raises USD10 Million in Second Tranche of Series A Financing Round 12
Syntimmune Raises USD8 Million in Venture Financing 13
Partnerships 14
Applied BioMath Enters into Agreement with Syntimmune 14
Acquisition 15
Alexion Pharma Acquires Syntimmune 15
Syntimmune Inc – Key Competitors 16
Syntimmune Inc – Key Employees 17
Syntimmune Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Jul 09, 2018: Syntimmune Appoints Mario Saltarelli As Chief Medical Officer 19
Apr 25, 2018: Syntimmune Appoints Andrew Cheng to Board of Directors, Bolstering Clinical Development Expertise 20
Jan 03, 2018: Syntimmune Appoints Jean-Paul Kress, M.D., as President and Chief Executive Officer 21
Product Approvals 22
Sep 12, 2018: Syntimmune announces FDA Orphan Drug Designation for SYNT001 in treatment of pemphigus 22
Clinical Trials 23
May 17, 2018: Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus 23
Feb 26, 2018: Syntimmune to Present Clinical Data on Lead Program SYNT001 at Plenary Session of International Investigative Dermatology Conference 24
Nov 01, 2017: Syntimmune Announces Clinical Data from First-in-Human Trial of Lead Candidate SYNT001 25
Mar 20, 2017: Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Syntimmune Inc, Pharmaceuticals & Healthcare, Key Facts 2
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syntimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syntimmune Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Syntimmune Raises USD50 Million in Series B Financing 10
Syntimmune Raises USD8 Million in Final Tranche of Series A Financing Round 11
Syntimmune Raises USD10 Million in Second Tranche of Series A Financing Round 12
Syntimmune Raises USD8 Million in Venture Financing 13
Applied BioMath Enters into Agreement with Syntimmune 14
Alexion Pharma Acquires Syntimmune 15
Syntimmune Inc, Key Competitors 16
Syntimmune Inc, Key Employees 17

List of Figures
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Syntimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Syntimmune Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bata India Limited
    Bata India Limited - Strategy, SWOT and Corporate Finance Report Summary Bata India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Pieridae Energy Ltd (PEA):石油・ガス:M&Aディール及び事業提携情報
    Summary Pieridae Energy Ltd (Pieridae Energy), formerly Petrolia Inc, is an oil and gas company that develops, explores, and produces oil resources. The company’s projects comprise Haldimand project, Bourque project, Tar Point project, Corte-Real project, Anticosti project, Dalhousie project; Edgar, …
  • Rousselot S.A.S.:企業の戦略・SWOT・財務情報
    Rousselot S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Rousselot S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sinovac Biotech Ltd (SVA):企業の財務・戦略的SWOT分析
    Summary Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company that develops, manufactures and commercializes vaccines. The company’s products comprise healive, a an inactivated hepatitis A vaccine; bilive, a combined inactivated hepatitis A and B vaccine; anflu, a split viron influenz …
  • Olympus Corp (7733):医療機器:M&Aディール及び事業提携情報
    Summary Olympus Corporation (Olympus) provides precision machinery and instruments. It develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and other industrial markets. It offers medical systems such as endotherapy devices, medical endoscopes and t …
  • Cathay Life Insurance Co Ltd:企業の戦略・SWOT・財務情報
    Cathay Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Cathay Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • International Finance Corporation:企業の戦略的SWOT分析
    International Finance Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Ambry Genetics Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • Tejas Networks Ltd (TEJASNET):企業の財務・戦略的SWOT分析
    Tejas Networks Ltd (TEJASNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cummins Inc.:企業の戦略・SWOT・財務分析
    Cummins Inc. - Strategy, SWOT and Corporate Finance Report Summary Cummins Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • JFE Holdings, Inc. (5411):企業の財務・戦略的SWOT分析
    JFE Holdings, Inc. (5411) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Haci Omer Sabanci Holding A.S. (SAHOL)-エネルギー分野:企業M&A・提携分析
    Summary Haci Omer Sabanci Holding A.S. (Sabanci) is an industrial and financial conglomerate. The company carries out banking, insurance, energy, retail, cement, insurance, automotive, tire and tire reinforcement materials businesses. The company has partnerships with various multinational business …
  • LegoChem Biosciences Inc (141080)-製薬・医療分野:企業M&A・提携分析
    Summary LegoChem Biosciences Inc (LCB) is a drug company that research and develops small molecule drugs. The company’s services include joint and contract research, chemical library package, compound synthesis and sales, and screening services. Its screening services include metabolic stability, pl …
  • NIKE Inc:戦略・SWOT・企業財務分析
    NIKE Inc - Strategy, SWOT and Corporate Finance Report Summary NIKE Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Centra Industries, Inc.:企業の戦略・SWOT・財務情報
    Centra Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Centra Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Addnode Group AB (ANOD B):企業の財務・戦略的SWOT分析
    Summary Addnode Group AB (Addnode) is an information technology company that supplies software and services for construction, design, and product data information. The company's solutions include design management solutions, process management solutions, and product lifecycle management solutions, a …
  • Nemus Bioscience Inc (NMUS):製薬・医療:M&Aディール及び事業提携情報
    Summary Nemus Bioscience Inc (Nemus Bioscience) is a life-science and biopharmaceutical company that offers discovering, developing and commercializing cannabinoid-based therapeutics. The company’s drug pipeline products include NB1111, NB1222, NB2111, NB2222 and Cannabinoid platform NB3111. Its can …
  • Sumitomo Bakelite Co Ltd (4203):企業の財務・戦略的SWOT分析
    Sumitomo Bakelite Co Ltd (4203) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Marathon Oil Corp (MRO):石油・ガス:M&Aディール及び事業提携情報
    Summary Marathon Oil Corp (MRO) is independent energy company, which explores, produces and markets liquid hydrocarbons and natural gas. It focuses mainly on unconventional resource plays in the US with operations in Africa and Europe. The company has properties in the major oil-rich resource plays …
  • PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaEssentia Corp (PharmaEssentia) is a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆